Synairgen Share Discussion Threads

[bobaxe1] 19/4/2020 18:11

Still happy its moved to urgent study show they must have seen a benefit in early patients imo.

[torreskid] 19/4/2020 18:09

GB is an investor nowt else

[torreskid] 19/4/2020 18:06

As a clinician, I believe, and have previously stated, that SNG001 will be of greater benefit in combination with a reliable antiviral agent (which one remains to be decided) Purely based on the logic of attacking this dreaded virus by more than one MOA, and using a combination which would have a lower risk/ side-effect profile (no point finding a cure or effective treatment if the side-effects are worse than the disease itself in the long run. (combining currently available antivirals agents is not so straight forward)

BTW There are still doubts over Remdesivir, but we definitely need a good antiviral agent

All IMHO, but pure conjecture until current study results published

[141jaffa] 19/4/2020 18:05

I think that's just a support the NHS profile logo.....it reads to me like an investor rather than anything else. TBF, every mention helps.

[torreskid] 19/4/2020 17:57

J Harries is the only one talking sense, in fact I feel she is always used as the scapegoat in these meetings (reminds me of wile coyote)

[jev1] 19/4/2020 17:49

This bit, maybe.

______

### She has operated at senior level in a number of organisations including Director of Marketing and Communications at Stockport NHS Foundation Trust, ###

[lukead] 19/4/2020 17:47

Re 4213, yes that would do nicely.
Re 4214, if that’s the same, then not a poster on here, what’s the NHS thingy on her twitter?

[nobbygnome] 19/4/2020 17:32

A good cv you have to say.....

[jev1] 19/4/2020 17:28

Gill Benning .... well, some of you did ask .... ;o)

_______


Huggon Associates

About us

On the sporting front, Gill is currently a Director of the Everybody Sport and Recreation Trust which manages and delivers sport and recreation centres and services on behalf of Cheshire East local authority.

Gill is an ex-full England hockey international and is a Level 2 England Hockey Coach - sometrhing she did to be able to give something back to the sport as a coach to young players. She is also Manager of the Pennine Pumas U17 Girls Junior Regional Performance Centre Squad which is part of the England Hockey performance system.

As a high level player, Gill was also England captain for several years. She quickly learned that few individuals can effectively lead their country in international sport without a clear understanding and appreciation of the need to ensure that the team works as a unit. If you can’t play as a team and don’t understand what is going on out on the pitch, there will be limited team cohesion, poor communication and you will most likely lose the game. Gill has found that this mirrors itself in business too!

As a result, she successfully applies best practice 'teamwork' principles to business practices today with great effect, mentors CEOs and Board members and runs dynamic self-development workshops.

If you are looking for some training with a difference for staff in your organisation - for example fundraising, marketing, mentoring, bidding, strategic planning, business development and you want something that will deliver real results get in touch today!

Gill has over 20 years’ experience in the education, sport, children and young people, health, disability and environment sectors.





### She has operated at senior level in a number of organisations including Director of Marketing and Communications at Stockport NHS Foundation Trust, ###





National Projects Director for the English Federation of Disability Sport and External Relations Director for the Lake District National Park Authority.

As CEO of the University of Wolverhampton Students Union Gill turned the organisation round from a £250k deficit to a secure £1m operating fund with new strategic, structural and cultural parameters.

As National Projects Director at the English Federation of Disability Sport she was instrumental in devising and delivering of a ground-breaking, sustainable national disability football programme, ‘Ability Counts’ in partnership with the FA, PFA, UMBRO, T- Mobile and professional football clubs throughout England.

The national success of ‘Ability Counts’ led directly to the FA establishing the national impairment specific squads we see today.

As a Senior Charities Aid Foundation Consultant, Gill has worked with over 500 charities, on a range of missions from generating income to turning round orgnaisations in crisis and mentoring Board's and CEOs. Charities Gill has worked with include the London Wildlife Trust, Womens Sports Foundation, Calvert Trust, People in Action, London Sports Forum, Council for the Protection of Rural Wales and Ryedale Charities Together.

As Director of Business and Resources for a large academy Gill successfully managed the school conversion to academy, restructured the 65 support staff and secured £3.3m capital development funding in 2 years. Since leaving the school, Gill has generated an additional £22m for academies, schools and charities across the UK.

Gill has many years’ experience of successfully devising and delivering positive, innovative, sustainable development projects and programmes and has a proven track record and reputation for consistently delivering superb, innovative value-added benefits for all.

[nobbygnome] 19/4/2020 17:17

Well there is no way that SNG can supply and market the drug globally on their own so would have to sign a licensing deal anyway. I guess any partner would probably want the whole lot to themselves so it makes sense to me. I suspect most shareholders would settile for £7-8 a share now rather than having to wait for sales to build.

I would be interested in others' thoughts....

[lukead] 19/4/2020 17:10

One guy worth looking at on LSE, imo is the poster ‘ sharesting’ he says he is a large investor and personally knows Richard M, seems to think it is is a given that on approval SNG will be taken over and that RM will be talking to Andrew Scott with in about a week or 2 weeks time. There are naturally lots of rampers and occasional derampers on both sites and it’s not always easy for us ordinary guys to spot the good guys.

[lukead] 19/4/2020 16:55

Really and so as I say, no one important, we disregard
Oh boy that Harries Doctor on the bbc has such a boring voice and completely loses me. The Minister with her is no better, such a nasal soft voice, waste of time.
All the Ministers apart from BJ and the Chancellor are imo useless. I am not a BJ fan, but at least he comes over as putting a bit of ‘welly’ into it.

[141jaffa] 19/4/2020 16:08

>> lukeadAs posted elsewhere.....looking at the bio, its quite possible they are on this bb !!

[mostro] 19/4/2020 15:49

dennisbergkamp

Transparency very unlikely with the potential billions of pounds at stake here for early vaccine success!!
As is the highly touted ' co-operation between various Pharma Companies working on vaccines and test kits ' and individual countries all sharing test info...
We saw what happened to co-operation in Europe when all the borders shut down after a few days..
Corporate greed will out here in a big and nasty way.. IMO

[lukead] 19/4/2020 15:39

No reply as to who Gill Benning is, so we can assume she is not a VIP

[daffodil4] 19/4/2020 15:34

Just wondering if posters here expect a takeover bid
if our trial is a success ? Also am I right
in thinking PI's would hold enough shares to have
a majority in the case of a vote, or do we need to
know where the placing shares went for that to be
known? Whatdo posters here feel is fair value for
the whole Company assuming the trial is a success..
the potential of our asthma treatement is surely
significant..A poster on LSE has said min of £15..
any other views???

[a.fewbob] 19/4/2020 15:31

Yes, leftist accademia on the make. If the research they undertake while being paid at the university has value then I would have thought the IP belonged to the university.

[dennisbergkamp] 19/4/2020 15:26

Dr Sarah - at best a conflict of interest.

I’m in but transparency is paramount
D

[adman50] 19/4/2020 13:10

Judging by bio one of us!

[nobbygnome] 19/4/2020 12:27

Who is Gill Benning?

[likya123] 19/4/2020 12:19

Another very interesting tweet found just now on lse board.
Ever get the sense you've found a life changing share in more ways than one?

I get the impression tomorrow is going to be a day to remember here...

[imjustdandy] 19/4/2020 12:05

Whatever the outcome there's going to be strong business fo is going forward. Just the start

[lauders] 19/4/2020 11:53

I think this may have been posted, surprised if it hasn't been, but a lot of posts since last looking and can't check every link since:

Other therapeutic approaches to modulate the body’s immune response
Interferon-β analogues

Interferons are proteins that stimulate the immune system to attack pathogens and other foreign cells (such as cancer cells). One class of interferons (called interferon-β) is of particular interest for treating COVID-19 since it activates cells that can engulf viruses. There are 11 trials of interferon drugs ongoing internationally. In the UK:

Researchers at the University of Southampton and Synairgen are testing an inhaled interferon-β drug (in development for asthma) in COVID-19 patients in several NHS Trusts. Previous research shows that the drugs can protect cells from other coronaviruses (MERS-CoV and SARS-CoV).